Trastuzumab in inflammatory breast cancer

Annals of Oncology

Volumn 19, Issue 10, 2008, Pages 1815-1817

  Mehta, R S ^a   Schubbert, T ^a   Kong, K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CARBOPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL; TRASTUZUMAB;

AREA UNDER THE CURVE; ARTHRALGIA; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; HEART DISEASE; HEART EJECTION FRACTION; HUMAN; LETTER; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; ONCOGENE NEU; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR VOLUME;

EID: 53049091927     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn555     Document Type: Letter

References (5)

1. Gonzalez-Angulo AM, Hennessy BT, Broglio K et al. Trends for inflammatory breast cancer: Is survival improving? Oncologist 2007; 12(8): 904-912.
2. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 2003; 21: 1431-1439.
3. Nguyen DM, Sam K, Tsimelzon A et al. Molecular heterogeneity of inflammatory breast cancer: A hyperproliferative phenotype. Clin Cancer Res 2006; 12(17): 5047-5054.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
5. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.